 "Lupin gets US FDA nod for antibacterial drug azithromycin suspension")
Lupin rose 7% to Rs 1,074 on the BSE after the pharmaceutical company reported a consolidated net profit of Rs 455 crore for the quarter ended September 2017 (Q2FY18). The analyst an average had expected profit of Rs 433 crore for the quarter.
Net profits for the quarter decreased by 31.3% compared to Rs 662 crore in Q2FY17.
Operational revenue of the company during the quarter however, declined by 8% at Rs 3,952 crore in Q2FY18 against Rs 4,291 crore in the corresponding quarter of previous fiscal.
EBITDA (earnings before interest, taxes, depreciation and amortization) margin improved
Net profits for the quarter decreased by 31.3% compared to Rs 662 crore in Q2FY17.
Operational revenue of the company during the quarter however, declined by 8% at Rs 3,952 crore in Q2FY18 against Rs 4,291 crore in the corresponding quarter of previous fiscal.
EBITDA (earnings before interest, taxes, depreciation and amortization) margin improved
